Business Description
Cipher Pharmaceuticals Inc
NAICS : 325412
SIC : 3741
ISIN : CA17253X1050
Compare
Compare
Traded in other countries / regions
CPH.CanadaCPHRF.USAPHE.Germany IPO Date
2015-03-23Description
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products among others. The company's geographical operational areas include Canada and the United States.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 161.98 | |||||
| Equity-to-Asset | 0.95 | |||||
| Debt-to-EBITDA | 0.03 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 41.72 | |||||
| Beneish M-Score | -2.26 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 3.4 | |||||
| 3-Year EBITDA Growth Rate | 16.4 | |||||
| 3-Year EPS without NRI Growth Rate | 41.2 | |||||
| 3-Year FCF Growth Rate | 17.8 | |||||
| 3-Year Book Growth Rate | 42.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 10.71 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 37.66 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.2 | |||||
| 9-Day RSI | 62.92 | |||||
| 14-Day RSI | 67.67 | |||||
| 6-1 Month Momentum % | 82.57 | |||||
| 12-1 Month Momentum % | 191.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 11.18 | |||||
| Quick Ratio | 10.59 | |||||
| Cash Ratio | 9.76 | |||||
| Days Inventory | 243.41 | |||||
| Days Sales Outstanding | 97.8 | |||||
| Days Payable | 441.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 3.8 | |||||
| Shareholder Yield % | 1.6 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 81.08 | |||||
| Operating Margin % | 49.8 | |||||
| Net Margin % | 101.77 | |||||
| FCF Margin % | 77.07 | |||||
| ROE % | 28.09 | |||||
| ROA % | 25.5 | |||||
| ROIC % | 50.24 | |||||
| 3-Year ROIIC % | 48.83 | |||||
| ROC (Joel Greenblatt) % | 444.55 | |||||
| ROCE % | 13.71 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 14.93 | |||||
| Forward PE Ratio | 14.3 | |||||
| PE Ratio without NRI | 14.3 | |||||
| Shiller PE Ratio | 78.53 | |||||
| Price-to-Owner-Earnings | 22.66 | |||||
| PEG Ratio | 0.69 | |||||
| PS Ratio | 14.86 | |||||
| PB Ratio | 3.56 | |||||
| Price-to-Tangible-Book | 4.47 | |||||
| Price-to-Free-Cash-Flow | 19.36 | |||||
| Price-to-Operating-Cash-Flow | 19.36 | |||||
| EV-to-EBIT | 26.94 | |||||
| EV-to-EBITDA | 24.45 | |||||
| EV-to-Revenue | 13.42 | |||||
| EV-to-Forward-Revenue | 5.86 | |||||
| EV-to-FCF | 17.08 | |||||
| Price-to-Projected-FCF | 1.89 | |||||
| Price-to-Median-PS-Value | 5.36 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.93 | |||||
| Price-to-Graham-Number | 1.7 | |||||
| Price-to-Net-Current-Asset-Value | 6.45 | |||||
| Price-to-Net-Cash | 7.47 | |||||
| Earnings Yield (Greenblatt) % | 3.72 | |||||
| FCF Yield % | 4.97 | |||||
| Forward Rate of Return (Yacktman) % | 19.27 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cipher Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 20.523 | ||
| EPS (TTM) (€) | 0.823 | ||
| Beta | 1.02 | ||
| Volatility % | 75.13 | ||
| 14-Day RSI | 67.67 | ||
| 14-Day ATR (€) | 0.419037 | ||
| 20-Day SMA (€) | 11.3025 | ||
| 12-1 Month Momentum % | 191.39 | ||
| 52-Week Range (€) | 2.8 - 12.7 | ||
| Shares Outstanding (Mil) | 25.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cipher Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cipher Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cipher Pharmaceuticals Inc Frequently Asked Questions
What is Cipher Pharmaceuticals Inc(STU:PHE)'s stock price today?
The current price of STU:PHE is €11.80. The 52 week high of STU:PHE is €12.70 and 52 week low is €2.80.
When is next earnings date of Cipher Pharmaceuticals Inc(STU:PHE)?
The next earnings date of Cipher Pharmaceuticals Inc(STU:PHE) is 2024-11-08 Est..
Does Cipher Pharmaceuticals Inc(STU:PHE) pay dividends? If so, how much?
Cipher Pharmaceuticals Inc(STU:PHE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers